GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Institutional Ownership

LTR Pharma (ASX:LTP) Institutional Ownership : 0.00% (As of Jun. 07, 2024)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, LTR Pharma's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, LTR Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, LTR Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

LTR Pharma Institutional Ownership Historical Data

The historical data trend for LTR Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Institutional Ownership Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Institutional Ownership
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Institutional Ownership - - -

LTR Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Institutional Ownership
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines